Ixazomib Production Cost Reports

The report provides a detailed analysis essential for establishing an Ixazomib manufacturing plant. It encompasses all critical aspects necessary for Ixazomib production, including the cost of Ixazomib production, Ixazomib plant cost, Ixazomib production costs, and the overall Ixazomib manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Ixazomib production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ixazomib is an oral proteasome inhibitor and finds its application in the pharmaceutical industry. It holds significant importance in the treatment of multiple myeloma. It works by blocking the proteasome to prevent cancer cell growth and promote cell death by targeting specific sites involved in protein regulation. It is prescribed with other medications as a combination therapy to individuals who have undergone at least one prior therapy. Its efficacy in controlling myeloma highlights its importance in the healthcare sector and its role in conducting research and development. Ixazomib proves as a versatile medicine with its potential benefits in combination drug therapy, making it a vital medication in various healthcare settings.

The primary market driver for Ixazomib is the prevalence of cancers, including multiple myeloma, all over the world. The increasing awareness among people, government policies as well as initiatives further boost the market growth for Ixazomib. Also, it serves as a vital medicine in research and development across the pharmaceutical industry, further pushing advancements in treatment options. Awareness of organizations and people towards ongoing demand dynamics relevant to its application in the healthcare sector further influences its procurement. Other factors like pharmaceutical regulations, along with supply, logistics, feedstocks, and trade policies, affect industrial Ixazomib procurement across the pharmaceutical and healthcare industries worldwide.

Raw Material for Ixazomib Production

According to the Ixazomib manufacturing plant project report, the key raw materials used in the production of Ixazomib include N-(2,5-Dichlorobenzoyl) Glycine and Borolane-Aminobutyric Acid.

Manufacturing Process of Ixazomib

The extensive Ixazomib production cost report consists of the following major industrial manufacturing process:

• From N-(2,5-Dichlorobenzoyl) Glycine and Borolane-Aminobutyric Acid: The manufacturing process of Ixazomib a condensation reaction. In this reaction, the carboxy group of N-(2,5-dichlorobenzoyl) glycine reacts with the amino group of borolane-aminobutyric acid. This reaction results in the formation of ixazomib citrate. Finally, the product is purified and separated to get Ixazomib as the final product.

Ixazomib is a glycine derivative with a complex molecular structure. Its molecular formula is C14H19BCl2N2O4, and it has a molecular weight of 361.0 g/mol. It demonstrates structural flexibility and a moderate level of polarity. It possesses hydrogen bond donor and acceptor sites, which indicates its potential for hydrogen bonding with other molecules. It is a white solid with a melting point in the range of 198 - 199 °C, and it is a relatively dense solid substance. It is soluble in various solvents such as chloroform, methanol, dichloromethane, and ethyl acetate. These physical and chemical properties collectively contribute to its medicinal properties.